PA
TERN

Parallel Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Parallel Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-416
Closed -$21.9K – 4069
2026
Q1 		$21.9K Buy
416
+68
+20% +$2.79K ﹤0.01% 2430
2025
Q4 		$14.1K Sell
348
-1,815
-84% -$41.9K ﹤0.01% 2471
2025
Q3 		$16.2K Hold
2,163
– – ﹤0.01% 2356
2025
Q2 		$8.07K Buy
2,163
+163
+8% +$509 ﹤0.01% 2565
2025
Q1 		$5.52K Buy
2,000
+1,663
+493% +$6.79K ﹤0.01% 2645
2024
Q4 		$1.87K Hold
337
– – ﹤0.01% 2994
2024
Q3 		$2.81K Hold
337
– – ﹤0.01% 2791
2024
Q2 		$2.29K Buy
337
+126
+60% +$763 ﹤0.01% 2780
2024
Q1 		$1.38K Buy
211
+97
+85% +$633 ﹤0.01% 2881
2023
Q4 		$740 Buy
+114
New +$603 ﹤0.01% 2999
2023
Q3 		– Sell
-161
Closed -$1.02K – 3483
2023
Q2 		$1.41K Hold
161
– – ﹤0.01% 2852
2023
Q1 		$1.91K Buy
+161
New +$1.54K ﹤0.01% 2794

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Parallel Advisors's TERN Position: Q2 2026 in Review

Parallel Advisors sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 416 shares — an estimated $21.9K sold.

Parallel Advisors first reported a position in TERN in Q1 2023 and held it in 12 quarters. The position peaked at $21.9K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Parallel Advisors reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Parallel Advisors sold 416 Terns Pharmaceuticals shares in Q2 2026, an estimated $21.9K.
  • Parallel Advisors first reported a position in Terns Pharmaceuticals in Q1 2023 and held it in 12 quarters.
  • Parallel Advisors's Terns Pharmaceuticals position peaked at $21.9K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.